ValuEngine has downgraded Synergy Pharmaceuticals SGYP (NYSE:SGYP) from Hold to Sell in a report released on 05/24/2017.
Recent Performance Chart
Synergy Pharmaceuticals SGYP has 52 week low of $2.56 and a 52 week high of $7.15 and has a market capitalization of $0.
A total of 5 equity analysts have released a research note on SGYP. Two brokers rating the stock a strong buy, 2 brokers rating the stock a buy, one brokerage rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $11.30.
More About Synergy Pharmaceuticals SGYP (NYSE:SGYP)
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.
The post Synergy Pharmaceuticals SGYP (NYSE:SGYP) has been downgraded from Hold to Sell in a statement by ValuEngine earlier today. appeared first on Octafinance.